Clinical trials
Completed Hepatitis B, Chronic trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
131 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 3 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 7 |
| 2009 | 10 |
| 2010 | 9 |
| 2011 | 5 |
| 2012 | 7 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 7 |
| 2019 | 3 |
| 2020 | 10 |
| 2021 | 10 |
| 2022 | 8 |
| 2023 | 6 |
| 2024 | 6 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 131 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 15 |
| GlaxoSmithKline | 12 |
| Beijing Ditan Hospital | 4 |
| Novartis | 4 |
| Novartis Pharmaceuticals | 4 |
| Shanghai HEP Pharmaceutical Co., Ltd. | 4 |
| Sunshine Lake Pharma Co., Ltd. | 4 |
| Xiamen Amoytop Biotech Co., Ltd. | 4 |
| Brii Biosciences Limited | 3 |
| Bristol-Myers Squibb | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hepatitis B, Chronic | 131 |
| Hepatitis B | 17 |
| Hepatitis | 7 |
| Fibrosis | 3 |
| Hepatitis, Chronic | 3 |
| Liver Cirrhosis | 2 |
| Non-alcoholic Fatty Liver Disease | 2 |
| Acute-On-Chronic Liver Failure | 1 |
| Carcinoma, Hepatocellular | 1 |
| DNA Virus Infections | 1 |
Trials
Showing 1 to 25 of 131. Each trial links to its page on Pharma Observatory.
31 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.